Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03603132
Other study ID # HR-TPO-Ig
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 14, 2018
Est. completion date August 17, 2018

Study information

Verified date May 2019
Source Jiangsu HengRui Medicine Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study use a single-center, randomized, open, three-cycle, self-control trial design. It is planning to enroll 15 healthy adult male subjects. Fifteen subjects will randomize into 3 test groups which corresponding to 3 different dosing sequences. Subjects will be giving a single oral dose in per cycle, and there will have three types of breakfast administration after each treatment. Washing period is 10 days during the cycle.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date August 17, 2018
Est. primary completion date August 17, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

1. Age = 18 years old

2. The subject's body weight was = 50.0 kg, BMI was between 19 and 26 kg/m2

3. Signed informed consent.

Exclusion Criteria:

1. Any clinically serious disease that has or is currently suffering from circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric, and metabolic abnormalities, or any other disease that can interfere with the test results

2. Having deep vein thrombosis or other thrombotic diseases.

3. Having thrombocytopenia, mitral valve prolapse, obvious heart murmur, or murmur.

4. Extended QT interval during the screening period (calculated in Bazett's method, males >450 msec)

5. Hepatitis B surface antigen, hepatitis C antibody, syphilis antibody, HIV antibody positive.

6. Those who have a history of allergies to drugs , food or test drugs or similar drugs;

7. Those who have undergone surgery within 4 weeks prior to the trial or plan to perform surgery during the study

8. Those who took any drug within 14 days before the test (including Chinese herbal medicine)

9. Any drug that inhibits or induces liver drug metabolism within 30 days before the test

10. Subjects have participated in other clinical trial within the 3 months prior to study entry.

11. One or more non-pharmacological contraceptive measures cannot be used during the trial, or it is planned to have birth within six months.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hetrombopag Olamine
7.5mg in each cycle

Locations

Country Name City State
China The third xiangya hospital Hospital,of central south university Changsha Hunan

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu HengRui Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse events from baseline up to Day 26
Secondary Peak Plasma Concentration (Cmax) pre-dose ,0.5 h? 1 h? 2 h? 4 h? 6 h? 7 h? 8 h? 10 h? 12 h? 24 h? 48 h? 72 h? 96 h? 120 h after giving dose in each group
Secondary Area under the plasma concentration versus time curve (AUC) pre-dose ,0.5 h? 1 h? 2 h? 4 h? 6 h? 7 h? 8 h? 10 h? 12 h? 24 h? 48 h? 72 h? 96 h? 120 h after giving dose in each group
See also
  Status Clinical Trial Phase
Completed NCT02287649 - Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP) N/A
Completed NCT02556814 - Caffeic Acid Combining High-dose Dexamethasone in Management of ITP Phase 4
Terminated NCT02401061 - PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP Phase 1/Phase 2
Completed NCT02868099 - Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP) Phase 3
Completed NCT02351622 - Caffeic Acid Tablets as a Second-line Therapy for ITP Phase 3
Active, not recruiting NCT04741139 - Post IVIG Medication in Children With Immune Thrombocytopenia Phase 1
Not yet recruiting NCT05494307 - The Combination of Terbutaline and Danazol as the Treatment of Corticosteroid-resistant/Relapse Immune Thrombocytopenia Phase 2
Not yet recruiting NCT05468866 - The Expression of Immune Checkpoint CD28 rs1980422-related Single-nucleotide Polymorphisms in the Primary Immune Thrombocytopenia N/A
Recruiting NCT05281068 - The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia Phase 2
Recruiting NCT04993885 - Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Phase 2
Not yet recruiting NCT05020288 - A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP Phase 2
Withdrawn NCT03965624 - Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia Phase 2
Not yet recruiting NCT03252457 - Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP Phase 3
Recruiting NCT05937828 - OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
Completed NCT03156452 - Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate Phase 3
Completed NCT03164915 - A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP) Phase 3
Recruiting NCT02270801 - Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy Phase 3
Completed NCT01933035 - Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias. N/A
Withdrawn NCT01976195 - High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP Phase 2
Recruiting NCT02821572 - Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)